表紙
企業レポート

PharmaPoint:季節性インフルエンザワクチン−−現在・将来の市場参入企業

PharmaPoint: Seasonal Influenza Vaccines - Current and Future Players

発行 GlobalData 商品コード 263600
出版日 ページ情報 英文 92 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
PharmaPoint:季節性インフルエンザワクチン−−現在・将来の市場参入企業 PharmaPoint: Seasonal Influenza Vaccines - Current and Future Players
出版日: 2012年11月30日 ページ情報: 英文 92 Pages
概要

当レポートでは、世界の季節性インフルエンザワクチン関連市場における既存企業および新規参入企業について分析し、市場全体の将来展望や促進・抑制要因、現在・将来の競争動向、主要企業のプロファイル(企業概要、事業展開、財務状況、SWOT分析)、市場全体と各企業の将来展望などを調査・考察して、その結果を概略以下の構成でお届けします。

第1章 目次

第2章 イントロダクション

第3章 市場の見通し

  • 世界市場
    • 予測
    • 促進・阻害要因:世界市場の課題

第4章 現在・将来の市場参入企業

  • 概要
  • 企業戦略の傾向
  • 企業プロファイル
    • Sanofi
    • AstraZeneca (MedImmune)
    • Novartis
    • GlaxoSmithKline
    • CSL Biotherapies
    • Abbott
    • Protein Sciences Corporation
    • Novavax

第5章 付録

図表一覧

目次
Product Code: GDHC1002FPR

Abstract

Summary

GlobalData has released its pharma report, "PharmaPoint: Seasonal Influenza Vaccines - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Seasonal Influenza Market. The report identifies and analyses the key companies shaping and driving the global Seasonal Influenza market. The report provides insight into the competitive Seasonal Influenza landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

  • Investigation of current and future market competition for Seasonal Influenza
  • Competitor assessment
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
  • Strategic assessment of the Seasonal Influenza sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Seasonal Influenza Market
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market
  • What's the next big thing in the global Seasonal Influenza market landscape? Identify, understand and capitalize

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Market Outlook

  • 3.1. Global Markets
    • 3.1.1. Forecast
    • 3.1.2. Drivers and Barriers - Global Issues

4. Current and Future Players

  • 4.1. Overview
  • 4.2. Trends in Corporate Strategy
  • 4.3. Company Profiles
    • 4.3.1. Sanofi
    • 4.3.2. AstraZeneca (MedImmune)
    • 4.3.3. Novartis
    • 4.3.4. GlaxoSmithKline
    • 4.3.5. CSL Biotherapies
    • 4.3.6. Abbott
    • 4.3.7. Protein Sciences Corporation
    • 4.3.8. Novavax

5. Appendix

  • 5.1. Bibliography
  • 5.2. Abbreviations
  • 5.3. Methodology
  • 5.4. Forecasting Methodology
    • 5.4.1. Vaccine Coverage
    • 5.4.2. Vaccines Included
    • 5.4.3. Key Launch Dates
    • 5.4.4. Influenza Vaccine Tender System Assumptions
    • 5.4.5. General Pricing Assumptions
    • 5.4.6. Individual Vaccine Assumptions
    • 5.4.7. Pricing of Pipeline Agents
  • 5.5. Physicians and Specialists Included in this Study
  • 5.6. Primary Research - Prescriber Survey
  • 5.7. About the Authors
    • 5.7.1. Authors
    • 5.7.2. Epidemiologists
    • 5.7.3. Global Head of Healthcare
  • 5.8. About GlobalData
  • 5.9. Contact Us
  • 5.10. Disclaimer

List of Tables

  • Table 1: Global Sales Forecasts ($m) for Influenza Vaccines, 2012-2022
  • Table 2: Influenza Vaccine Market - Drivers and Barriers, 2012
  • Table 3: Key Companies in the Seasonal Influenza Vaccine Market, 2012
  • Table 4: Sanofi's Seasonal Influenza Vaccine Portfolio Assessment, 2012
  • Table 5: Sanofi SWOT Analysis, 2012
  • Table 6: AstraZeneca's Seasonal Influenza Vaccine Portfolio Assessment, 2012
  • Table 7: AstraZeneca SWOT Analysis, 2012
  • Table 8: Novartis' Seasonal Influenza Vaccine Portfolio Assessment, 2012
  • Table 9: Novartis SWOT Analysis, 2012
  • Table 10: GlaxoSmithKline's Seasonal Vaccine Portfolio Assessment, 2012
  • Table 11: GlaxoSmithKline's SWOT Analysis, 2012
  • Table 12: CSL Biotherapies' Seasonal Vaccine Portfolio Assessment, 2012
  • Table 13: CSL Biotherapies SWOT Analysis, 2012
  • Table 14: Abbott's Seasonal Vaccine Portfolio Assessment, 2012
  • Table 15: Abbott SWOT Analysis, 2012
  • Table 16: Protein Science's Seasonal Vaccine Portfolio Assessment, 2012
  • Table 17: Protein Sciences SWOT Analysis, 2012
  • Table 18: Novavax's Seasonal Vaccine Portfolio Assessment, 2012
  • Table 19: Novavax SWOT Analysis, 2012
  • Table 20: Epidemiology and Market Forecast Chinese Influenza Vaccination Rates (%), 2012-2022
  • Table 21: Key Launch Dates
  • Table 22: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Global Sales of Influenza Vaccines by Region, 2012-2022
  • Figure 2: Company Portfolio Gap Analysis in Seasonal Influenza Vaccines, 2012-2022
Back to Top